Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers - PubMed (original) (raw)
Clinical Trial
Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers
Eric Siemers et al. Clin Neuropharmacol. 2005 May-Jun.
Abstract
Amyloid beta (Abeta) may play a central role in the pathogenesis of Alzheimer disease. A functional gamma-secretase inhibitor, LY450139, was developed that inhibits Abeta formation in whole cell assays, transgenic mice, and beagle dogs. The authors wished to determine the safety and tolerability of this drug, and the reduction of Abeta in plasma and cerebrospinal fluid (CSF) after multiple doses. Volunteer subjects (N = 37) were studied using doses from 5 to 50 mg/day given for 14 days. Plasma and CSF concentrations of LY450139, Abeta(1-40) and Abeta(1-X) ("Abeta(total)") were determined, and safety and tolerability were assessed. The plasma half-life of LY450139 was approximately 2.5 hours. Pharmacokinetic analyses showed a linear relationship between dose and plasma concentrations, with a Cmax of 828 +/- 19.2 ng/mL after a 50-mg dose. Plasma Abeta concentrations decreased in a dose-dependent manner over a 6-hour interval following drug administration, with a maximum decrease of approximately 40% relative to baseline. After returning to baseline, Abeta concentrations were transiently increased. CSF Abeta concentrations were unchanged. Adverse events reported by subjects taking 5-mg, 20-mg, or 40-mg doses were similar to those reported by subjects taking placebo. Two of 7 subjects taking 50 mg/day experienced adverse events that may have been drug related. In this phase 1 volunteer study, reported adverse events after taking LY450139 were manageable. A dose-dependent reduction in plasma Abeta was demonstrated, and changes in plasma Abeta concentrations were temporally related to the pharmacokinetic characteristics of LY450139.
Similar articles
- Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Fleisher AS, et al. Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031. Arch Neurol. 2008. PMID: 18695053 Free PMC article. Clinical Trial. - Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Siemers ER, et al. Clin Neuropharmacol. 2007 Nov-Dec;30(6):317-25. doi: 10.1097/WNF.0b013e31805b7660. Clin Neuropharmacol. 2007. PMID: 18090456 Clinical Trial. - Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR. Best JD, et al. J Pharmacol Exp Ther. 2005 May;313(2):902-8. doi: 10.1124/jpet.104.081174. Epub 2005 Mar 2. J Pharmacol Exp Ther. 2005. PMID: 15743924 - Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.
Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K. Portelius E, et al. Neurodegener Dis. 2012;10(1-4):138-40. doi: 10.1159/000334537. Epub 2012 Feb 1. Neurodegener Dis. 2012. PMID: 22302034 Review. - Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A. D'Onofrio G, et al. Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Expert Opin Drug Discov. 2012. PMID: 22468891 Review.
Cited by
- Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.
Athar T, Al Balushi K, Khan SA. Athar T, et al. Mol Biol Rep. 2021 Jul;48(7):5629-5645. doi: 10.1007/s11033-021-06512-9. Epub 2021 Jun 28. Mol Biol Rep. 2021. PMID: 34181171 Free PMC article. Review. - Predicting the frequencies of drug side effects.
Galeano D, Li S, Gerstein M, Paccanaro A. Galeano D, et al. Nat Commun. 2020 Sep 11;11(1):4575. doi: 10.1038/s41467-020-18305-y. Nat Commun. 2020. PMID: 32917868 Free PMC article. - Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase.
Steiner H, Fukumori A, Tagami S, Okochi M. Steiner H, et al. Cell Stress. 2018 Oct 28;2(11):292-310. doi: 10.15698/cst2018.11.162. Cell Stress. 2018. PMID: 31225454 Free PMC article. Review. - γ-Secretase and its modulators: Twenty years and beyond.
Xia W. Xia W. Neurosci Lett. 2019 May 14;701:162-169. doi: 10.1016/j.neulet.2019.02.011. Epub 2019 Feb 11. Neurosci Lett. 2019. PMID: 30763650 Free PMC article. Review. - The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer's disease.
Gerber H, Mosser S, Boury-Jamot B, Stumpe M, Piersigilli A, Goepfert C, Dengjel J, Albrecht U, Magara F, Fraering PC. Gerber H, et al. Acta Neuropathol Commun. 2019 Jan 31;7(1):13. doi: 10.1186/s40478-019-0660-3. Acta Neuropathol Commun. 2019. PMID: 30704515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources